miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 9, 2026

The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8%

View original at nasdaq.com
The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8% The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • More than 10,000 rare diseases exist today but only 5% have approved medicines

    80% confidence
  • Keytruda won't start to lose exclusivity until late 2028

    80% confidence
  • U.S. housing market is begging for investment - industry has been underbuilding for years and nearly three-quarters of existing homes are 25 years old or greater

    80% confidence
  • 5 Hidden Yield dividend stocks are poised to deliver 15% annualized returns - enough to double investment every 5 years

    80% confidence
  • Verizon is falling short of its potential and needs to improve loyalty, retention, and operational efficiency

    80% confidence
  • GLP-1 drugs can't put a dent in Coca-Cola despite worries from bears

    80% confidence
  • Dogs of the Dow strategy works because it is contrarian - high yields for blue chips signal value as these stocks are out of favor, not going out of business

    80% confidence
  • Experts estimate it would take tens of billions of dollars of investment and many years to meaningfully ramp up oil production in Venezuela

    80% confidence
  • Uncertain economic environment with mixed indicators - some like GDP and PCE are strong, but housing pressure and consumer uncertainty are impacting home improvement

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com